Long-term immunotherapy with low-dose interleukin-2 and interferon-? in the treatment of patients with advanced renal cell carcinoma
- 1 November 2001
- Vol. 92 (9), 2286-2296
- https://doi.org/10.1002/1097-0142(20011101)92:9<2286::aid-cncr1575>3.0.co;2-i
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Effectiveness of very low doses of immunotherapy in advanced renal cell cancerBritish Journal of Cancer, 1997
- Low doses of rIL2 after autologous bone marrow transplantation induce a “prolonged” immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomasAnnals of Hematology, 1995
- A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspectsBritish Journal of Cancer, 1993
- Low-Dose lnterleukin-2 in Combination with Interferon-α Effectively Modulates Biological Response in vivoActa Haematologica, 1993
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.The Journal of Experimental Medicine, 1990
- Cancer Immunotherapy: Current Status of Treatment With Interleukin 2 and Lymphokine-Activated Killer CellsMayo Clinic Proceedings, 1989
- Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.Journal of Clinical Oncology, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987